Pharmaceuticals
Eli Lilly Introduces Affordable Version of Zepbound to Address Soaring Demand and Combat Counterfeit Drugs
New Single-Dose Vials of Zepbound Priced at Half the Cost Aim to Increase Access for Uninsured Patients Eli Lilly (LLY)...
Conduit Pharmaceuticals Secures Exclusive Licensing Agreement with AstraZeneca for Novel Therapeutics
Phase II Trials Set to Begin on Glucokinase Activators and Myeloperoxidase Inhibitor Targeting Autoimmune Disorders and Male Infertility Conduit Pharmaceuticals...
Corbus Pharmaceuticals: Pioneering Next-Generation Therapies in Cancer and Obesity
Revolutionary Treatments on the Horizon with CRB-701 and CRB-913 Corbus Pharmaceutical (CRPB), an early-stage clinical biotechnology company, is making significant...
TARS Pharmaceuticals: XDEMVY Eye Drops Set for Strong Performance in 2Q24 Amid Strategic Sales Expansion
Anticipated Growth in XDEMVY Sales, Sales Force Expansion, and Promising Pipeline Signal a Bright Future for TARS Pharmaceuticals As we...
Why Are These Stocks Surging Today?
Examining the Unprecedented Moves of Windtree Therapeutics, Regencell Therapeutics, and Coursera In the ever-fluctuating stock market, certain companies stand out...
Breakthrough in Hemophilia A Treatment: Pfizer’s Gene Therapy Shows Promising Results
AFFINE Study Demonstrates Superiority of Giroctocogene Fitelparvovec Over Routine Prophylaxis Pfizer (PFE) recently announced encouraging results from the Phase 3...
Adial Pharmaceuticals Advances with Promising Study for Alcohol Use Disorder Treatment
Successful Progression to Second Cohort in AD04 Pharmacokinetics Study Adial Pharmaceuticals (ADIL), a clinical-stage biopharmaceutical company dedicated to developing therapies...
Future Directions in Obesity Treatment: Survey Insights and Innovations
Exploring New Frontiers in Effective Weight Management Obesity continues to be a pressing global health issue, necessitating the continual evolution...
CALC’s Promising Prospects in Severe Acute Kidney Injury: A Billion-Dollar Opportunity
First Patient Dosed in Phase 2 Trial CALC has reached a significant milestone in its journey to address severe acute...
Cathie Wood’s Strategic Moves: A Deep Dive into ARK Investment Management’s Latest Trades
Balancing Biotech Bets with Emerging Tech and Aerospace Cathie Wood, the visionary behind ARK Investment Management, is known for her...
